Topics

RNA Binding Proteins & Cardiovascular Health

Chronic Inflammation Intercellular Communication & Diseases Cellular Stress

RNA-binding proteins (RBPs) are proteins that directly bind RNA and regulate post-transcriptional gene expression through RNA splicing, maturation, localization, stability, and translation. Cardiovascular studies show that RBPs participate in heart development, cardiomyocyte function, endothelial homeostasis, inflammatory signaling, and tissue repair. RBP dysregulation is linked to heart failure, cardiomyopathy, atherosclerosis, myocardial infarction, and vascular dysfunction. Quaking, HuR, Muscleblind, SRSF1, RBM20, and RBFOX proteins have emerged as key regulators of cardiovascular health and disease because they control RNA fate during cellular phenotype switching and stress responses[1][2][3][4].
Mechanistically, RBPs regulate cardiovascular post-transcriptional networks by recognizing defined RNA sequences or RNA structures. RBM20 controls cardiac pre-mRNA splicing, and RBM20 mutations are implicated in dilated cardiomyopathy. HuR binds AU-rich regions in target mRNAs and regulates mRNA stability or translation; HuR activation increases in failing human hearts, and HuR inhibition reduces pressure-overload-induced cardiac hypertrophy, dilation, fibrosis, and functional decline in experimental models. QKI binds VE-cadherin and β-catenin mRNAs and supports endothelial barrier function. In heart failure, reactivation of fetal-specific RBPs is associated with transcriptome-wide expression of fetal-specific isoforms, linking RBP activity to pathological cardiac remodeling[4][5][6][7].
In disease-oriented research, RBPs provide experimental entry points for cardiomyopathy mechanisms, heart-failure transcriptome remodeling, vascular inflammation, atherosclerosis, myocardial injury repair, and RNA-targeted therapeutic discovery. Their therapeutic relevance comes from their ability to coordinate RNA processing programs rather than single downstream genes. Major unresolved challenges include complex substrate specificity, strong cell-type dependence, limited integration of transcriptomic and proteomic datasets, and insufficient availability of selective RBP modulators. Future studies should combine CLIP-seq, single-cell transcriptomics, spatial omics, and functional perturbation screens to define RBP-RNA interaction networks and support precision RNA-regulatory therapies for cardiovascular disease[1][2][7][8].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-13418 Dorsomorphin dihydrochloride
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
Colorectal Cancer   Prostate Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity  
819
HY-13418A Dorsomorphin
Dorsomorphin (BML-275) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
819
HY-10431 SB-431542
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
Organoid   TGF-β Receptor   Apoptosis  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Digestive System Inflammation   Obesity   Lung Fibrosis  
323
HY-10182 Laduviglusib
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.
Organoid   GSK-3   Wnt   β-catenin   Autophagy  
Breast Cancer   Pancreatic Cancer   Depression   Glucose Metabolism   Alzheimer's Disease   Obesity   Lung Fibrosis  
321
HY-10201A Sorafenib tosylate
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family  
Neurological, Eye or Ear Disease   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
316
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
316
HY-100381 Nigericin sodium salt
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.

Source: Streptomyces hygroscopicus

Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-127019 Nigericin
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-15147 XAV-939
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation.
β-catenin   PARP  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Hypertension   Lung Fibrosis  
209
HY-50896 Erlotinib
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
EGFR   OAT   ERK   GSK-3   β-catenin  
Gastric Cancer   Pancreatic Cancer   Renal Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma  
147
HY-10432 A 83-01
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
Organoid   TGF-β Receptor  
Cancer  
144
HY-L068 Flavonoids Library
Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc. MCE offers a unique collection of 583 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.

Structure Classified Natural Product Libraries

98
HY-12071 LDN193189
LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
Organoid   TGF-β Receptor  
Breast Cancer  
95
HY-L078 Gut Microbial Metabolite Library
Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods. In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

Metabolism Focused Libraries

85
HY-L046 Anti-Cardiovascular Disease Compound Library
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 2,468 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Disease Focused Libraries

84
HY-L094 Food-Sourced Compound Library
The health benefits deriving from the consumption of certain foods have been common knowledge. All foods are made up of chemical substances. Chemicals in foods are largely harmless and often desirable. At present, numerous researchers have been focused on the beneficial role played by certain food components in the close relationship between food intake and health status. For example, polyphenols, a common class of compounds among foods, are well-known antioxidants, which may play a role in the prevention of several diseases including type 2 diabetes, cardiovascular diseases, and some types of cancer. MCE supplies a unique collection of 2,064 compounds from variety of foods. All compounds are with specific food source(s). MCE Food-Sourced Compound Library is the useful tool to discover molecules with pharmaceutical activity from foods.

Compound Characteristic Classified Libraries

84
HY-L087 Anti-Obesity Compound Library
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Disease Focused Libraries

83
HY-L119 Potassium Channel Compound Library
Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. There are four major classes of K channels: voltage-gated potassium channel, calcium-activated potassium channel, inwardly rectifying potassium channel and tandem pore domain potassium channel. There is growing evidence that dysfunction in potassium channels correlates with several diseases, such as chronic hypertension, diabetes, hypercholesterolemia and atherosclerosis, etc. MCE Potassium Channel Compound Library consists of 337 potassium channel inhibitor and activators, which is a useful tool to discover drugs for cardiovascular diseases and potassium channel research.

Signaling Pathway Targeting Libraries

83
HY-L185 Anti-Fibrosis Compound Library
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Disease Focused Libraries

83
HY-L191 Tibetan Medicine Compound Library
Tibetan medicine, as one of the treasures of traditional Chinese medicine, carries the profound cultural heritage of the Tibetan people and their unique understanding of health. Tibet is the birthplace of Tibetan medicine, and its plateau climate and unique ecological environment have nurtured its rich medicinal resources. Among them, cordyceps, saffron and snow lily are favored by people for their excellent medicinal value and unique growth characteristics. Tibetan medicine, with its profound heritage, plays a crucial role in the management of diseases that are unique to high-altitude regions, such as altitude stress. It facilitates a swifter adaptation to high-altitude conditions and mitigates the symptoms of altitude sickness by meticulously recalibrating the internal environment within the human body. For rheumatic diseases, cardiovascular diseases, etc., Tibetan medicine has also shown its remarkable effect. MCE included 1,146 natural products from Tibetan medicine, including animal, plant and mineral sources.
83
HY-L208 Bile Acids Library
Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases. MCE included 62 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.
83
HY-L248 RNA Binding Bioactive Compound Library
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development. The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Signaling Pathway Targeting Libraries

83
HY-L265 Cholesterol Metabolism Compound Library
Cholesterol is a crucial lipid that maintains cell membrane structure, serves as a precursor for the synthesis of steroid hormones and bile acids, and plays an important role in cell signal transduction and membrane function regulation. Intracellular cholesterol levels are precisely controlled by multiple processes, including synthesis, uptake, transport, esterification, storage, and efflux. Dysregulation of cholesterol metabolism is closely associated with diseases such as atherosclerosis, fatty liver disease, metabolic syndrome, and various cancers. The Cholesterol Metabolism Compound Library contains 558 compounds and focuses on cholesterol metabolism and homeostatic regulation. It provides an efficient tool for mechanistic studies of cholesterol metabolism and for drug discovery in metabolism‑related diseases.
83
HY-L917 RNA Binding Library
RNA is crucial for the regulation of numerous cellular processes and functions. With the in-depth study of disease mechanisms, processes such as RNA expression, splicing, translation, and stability regulation have become new targets for disease intervention. RNA has provided new therapeutic modalities for metabolic diseases, genetic disorders, and cancer patients, resulting in several innovative drugs. MCE R&D team collected small molecules targeting RNA from the PDB, R-BIND, ROBIN, and internal database as the positive dataset, and non-targeting RNA small molecules from ROBIN as the negative dataset. Based on the GeminiMol pre-trained model, we encoded the molecules and calculated over 1700 molecular descriptors using Mordred as inputs for the model. Subsequently, we employed 13 deep learning models to learn from the data. All of which yielded good training results, with AUROCs greater than 0.75. Ultimately, we selected the Finetune model to screen HY-L901P, which exhibited the best classification performance, achieving an AUROC of 0.82 and a prediction accuracy of 0.76. We then applied filtering based on StaR rules (with at least two of the following properties: cLogP ≥ 1.5, Molar Refractivity ≥ 4, Relative Polar Surface Area ≤ 0.3) to obtain a library containing approximately 5,000 small molecule compounds targeting RNA. This library serves as a valuable tool for screening small molecules that interact with RNA.

Focused and target libraries

83
HY-L923 Ion Channel Lead-like Compound Library
Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields. MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-13226 Galunisertib
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
TGF-β Receptor  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
74
HY-14428 ICG-001
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
β-catenin   Apoptosis  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Hypertension   Lung Fibrosis  
68
HY-101085 SKL2001
SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.
Wnt   β-catenin  
Cancer   Depression   Obesity  
67
HY-120697 MSAB
MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin and promotes its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells.
Wnt   β-catenin  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
60
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-B0573 Propranolol hydrochloride
Propranolol hydrochloride is a nonselective and BBB-permeableβ-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor   Bacterial  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Depression   SARS-CoV-2 Infection   Alzheimer's Disease   Hypertension  
52
HY-B0573B Propranolol
Propranolol is a nonselective and BBB-permeable β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor   Bacterial  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Alzheimer's Disease   Psoriasis   Hypertension  
52
HY-16954 ARV-825
ARV-825 is a BET protein PROTAC degrader that recruits cereblon, and it targets BRD2, BRD3, and BRD4 for degradation via the ubiquitin-proteasome pathway. ARV-825 downregulates c-MYC, PLK1, MYCN, CDK4/6, JAK2, pSTAT3/5, PIM1, and Bcl-xL, upregulates p21 and p27, and modulates H3K27Ac-mediated transcription, the G2/M checkpoint, the Wnt/β-catenin pathway, and amino acid transport pathways. ARV-825 induces G1 phase cell cycle arrest, caspase 3/PARP-mediated apoptosis, DNA damage, and reactive oxygen species (ROS) production, reduces mitochondrial respiration, and simultaneously inhibits cell proliferation, clonogenic growth, and cell migration. ARV-825 is used in research on gastric cancer, leukemia, neuroblastoma, and cholangiocarcinoma.
PROTACs   Epigenetic Reader Domain   c-Myc   Polo-like Kinase (PLK)   CDK   JAK   STAT   Pim   Bcl-2 Family   PAK   Wnt   β-catenin   Caspase   PARP   Apoptosis   Reactive Oxygen Species (ROS)  
Gastric Cancer   Leukemia/Lymphoma/Myeloma   Neuroblastoma  
37
HY-13012 RepSox
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.
Organoid   TGF-β Receptor  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Glucose Metabolism   Obesity   Lung Fibrosis  
23
HY-N0527 Pentagalloylglucose
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities.
JAK   Keap1-Nrf2   Apoptosis   β-catenin   Reactive Oxygen Species (ROS)   E1/E2/E3 Enzyme  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
16
HY-103248 Toyocamycin
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM.

Source: Streptomyces diastatochromogenes

IRE1   Fungal   Antibiotic   Apoptosis   CDK  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Fungal Infection   Digestive System Inflammation  
15
HY-12273 DMH-1
DMH-1 is a selective BMP inhibitor. DMH-1 upregulates the expression of SOX1. DMH-1 increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
TGF-β Receptor   Organoid   Microtubule/Tubulin  
Neurological, Eye or Ear Disease   Heart Disease  
15
HY-113071 Mevalonic acid
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
13
HY-113071A Mevalonic acid lithium salt
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Cardiovascular Disease  
13
HY-N2037 Higenamine
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases.
MAP3K   MDM-2/p53   Adrenergic Receptor   ROS Kinase   Apoptosis  
Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity  
12
HY-N0935 Ligustrazine hydrochloride
Ligustrazine hydrochloride (Chuanxiongzine hydrochloride) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine hydrochloride reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine hydrochloride possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.
Reactive Oxygen Species (ROS)   Akt   NO Synthase   Aminotransferases (Transaminases)  
Cerebrovascular Disease   Lipid Metabolism   Ischemia-Reperfusion Injury   Atherosclerosis and Inflammation  
11
HY-15664 Bivalirudin TFA
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others.
Thrombin   Interleukin Related   RSV  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
11
HY-P1929 Bivalirudin
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others.
Thrombin   Interleukin Related   RSV  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
11
HY-N0264 Ligustrazine
Ligustrazine (Chuanxiongzine) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.
Reactive Oxygen Species (ROS)   Akt   NO Synthase   Aminotransferases (Transaminases)  
Cerebrovascular Disease   Lipid Metabolism   Ischemia-Reperfusion Injury   Atherosclerosis and Inflammation  
11
HY-13541 ADH-1
ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
Cadherin  
Cancer  
10
HY-N6653 Lentinan
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering.
JAK   Keap1-Nrf2   Apoptosis  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
9
HY-D2295 Mito-FerroGreen
Mito-FerroGreen is a mitochondria-specific Fluorescent indicator used to detect mitochondrial Fe2+ levels (excitation: 488 nm; emission: 500-550 nm). Mito-FerroGreen can be applied to research related to colorectal cancer and chronic heart failure.
Fluorescent Dye  
Colorectal Cancer   Heart Failure  
7
HY-N0853 Alisol A
Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity.
AMPK   Acetyl-CoA Carboxylase   PPAR   MMP   Interleukin Related  
Breast Cancer   Colorectal Cancer   Glucose Metabolism   Atherosclerosis   Obesity  
5
HY-D0098 Fluorescein-5-maleimide
Fluorescein-5-maleimide (N-(5-Fluoresceinyl)maleimide) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiac myosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm.
Fluorescent Dye  
5
HY-P0119A Lixisenatide acetate
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
GLP Receptor   Akt   MEK   Reactive Oxygen Species (ROS)   Apoptosis   MMP  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
4
HY-106262B Delcasertib hydrochloride
Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).
PKC  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
4
HY-A0143 Dihomo-γ-linolenic acid
Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system.
Endogenous Metabolite  
Inflammation or Immune System Disease   Acute Myeloid Leukemia   Atherosclerosis  
4
HY-NP013 Oxidized low density lipoprotein (mouse)
Oxidized low density lipoprotein (mouse) (Mouse ox-LDL) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration. Oxidized low density lipoprotein (mouse) can be used to construct an in vitro model of AS.
LDLR   ROR   β-catenin  
Blood or Cardio-cerebrovascular Disease  
4
HY-112537 D-Glucose 6-phosphate
D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
Endogenous Metabolite   mTOR  
Heart Failure   Glycolysis  
4
HY-44134 Dimethyl 2-oxoglutarate
Dimethyl 2-oxoglutarate (Dimethyl α-ketoglutarate) is a cell-permeable derivative of 2-oxoglutarate and tricarboxylic acid cycle metabolite with antioxidant properties. Dimethyl 2-oxoglutarate inhibits Autophagy. Dimethyl 2-oxoglutarate prevents mitochondrial damage and reduces ROS production. Dimethyl 2-oxoglutarate alleviates Carbon tetrachloride (HY-Y0298)-induced liver fibrosis. Dimethyl-2-oxoglutaric acid can be used in the research of diseases such as Alzheimer's disease, diabetes, and cardiomyopathy.
Endogenous Metabolite   Drug Derivative   Autophagy   Mitochondrial Metabolism   Reactive Oxygen Species (ROS)  
Glucose Metabolism   Alzheimer's Disease   Cardiomyopathy   Hepatic Fibrosis  
4
HY-112537A D-Glucose 6-phosphate dipotassium
D-Glucose 6-phosphate dipotassium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate dipotassium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate dipotassium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
Endogenous Metabolite   mTOR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
3
HY-P2141A TRV-120027 TFA
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling. TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment.
Angiotensin Receptor   Arrestin  
Cardiovascular Disease  
3
HY-N2963 Broussonin E
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis.
ERK   p38 MAPK   JAK   STAT   TNF Receptor   Interleukin Related   COX   Arginase  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
3
HY-P2141 TRV-120027
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling. TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment.
Angiotensin Receptor   Arrestin  
Blood or Cardio-cerebrovascular Disease  
3
HY-112537B D-Glucose 6-phosphate sodium
D-Glucose 6-phosphate sodium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate sodium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate sodium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
Endogenous Metabolite   mTOR  
Metabolic or Endocrine Disease   Heart Failure  
3
HY-P99355 Bimagrumab
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.

Species: Human

TGF-β Receptor  
Metabolic or Endocrine Disease  
3
HY-P4911 SDF-1α (human)
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research.
CXCR  
Blood or Cardio-cerebrovascular Disease  
2
HY-124806 TTP-8307
TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP).
Enterovirus   DNA/RNA Synthesis   HCV  
Viral Infection   Hepatitis C Virus Infection  
2
HY-B0268 Enoxacin
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
Bacterial   DNA/RNA Synthesis   MicroRNA   Antibiotic  
Cancer   Bacterial Infection  
2
HY-N0419 Quercimeritrin
Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer.
Glycosidase   c-Kit   MMP   VEGFR   Aurora Kinase  
Breast Cancer   Type 2 Diabetes  
2
HY-B0268A Enoxacin hydrate
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
Bacterial   DNA/RNA Synthesis   MicroRNA   Antibiotic  
Cancer   Bacterial Infection   SARS-CoV-2 Infection  
2
HY-107825 Flavonol
Flavonol is a cholinesterase (ChE) inhibitor, with an IC50 value of 120 μM and a Ki value of 74 μM. Flavonol has antioxidant, free radical-scavenging, antibacterial properties, and immune modulation functions. Flavonol inhibits the PriA helicase of Staphylococcus aureus. Flavonol can suppress the production of NO in LPS-activated RAW 264.7 cells by inhibiting the expression of the iNOS enzyme. Flavonol shows protective and analgesic effects in mice through various neuronal pathways. Flavonol can be used in research related to tumors and atherosclerosis diseases.
Endogenous Metabolite   Bacterial   Cholinesterase (ChE)  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Bacterial Infection   Cardiovascular Disease   Lung Fibrosis  
2
HY-P4911A SDF-1α (human) TFA
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research.
CXCR  
Blood or Cardio-cerebrovascular Disease  
2
HY-N1990 Gypenoside XLIX
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
PPAR   Sirtuin   Keap1-Nrf2   Toll-like Receptor (TLR)   NF-κB   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   Apoptosis   Pyroptosis   Autophagy  
Neurological, Eye or Ear Disease   Atherosclerosis and Inflammation   Acute Lung Injury   Cardiomyopathy   Liver Injury  
2
HY-N0086R N6-Methyladenosine (Standard)
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion. N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits.
Endogenous Metabolite   Reference Standards   Influenza Virus  
Infection  
2
HY-P99646 Golocdacimab
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.

Species: Human

LOX-1  
Type 1 Diabetes   Atherosclerosis and Inflammation  
2
HY-153918 (R)-SKBG-1
(R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC50 of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer.
Androgen Receptor  
Prostate Cancer  
2
HY-124828 CMLD-2
CMLD-2, an inhibitor of HuR-ARE interaction, competitively binds HuR protein disrupting its interaction with adenine-uridine rich elements (ARE)-containing mRNAs (Ki=350 nM). CMLD-2 induces apoptosis exhibits antitumor activity in different cancer cells as colon, pancreatic, thyroid and lung cancer cell lines. Hu antigen R (HuR) is an RNA binding protein, can regulate target mRNAs stability and translation.
HuR  
Lung Cancer  
2
HY-P99053 Tralokinumab
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.

Species: Human

Interleukin Related   Apoptosis   Caspase   Cadherin  
Asthma   Lung Fibrosis  
2
HY-P991218 Anti-IL11 Antibody (X203)
Anti-IL11 Antibody (X203) (EnX203) is a human-derived IgG1, κ type antibody inhibitor, targeting to human IL-11. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Interleukin Related   ERK   STAT   CDK   Cadherin  
Inflammation or Immune System Disease   Lung Fibrosis  
2
HY-125864 Fibrinogen (Bovine)
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases.
Interleukin Related   NF-κB  
Inflammation or Immune System Disease  
2
HY-E70182 Hyaluronidase 2
Hyaluronidase 2 (EC:3.2.1.35; HYAL2) is a hyaluronidase. Hyaluronidase 2 cleaves high-molecular-weight hyaluronan into intermediate, ~20 kDa, and tetrasaccharide fragments. Hyaluronidase 2 directly interacts with CD44 and ERM proteins, reduces CD44 hyaluronan binding capacity and ERM activation. Hyaluronidase 2 can be used for the research of gliomas, inflammatory bowel disease, congenital heart defects, heart failure.
CD44  
Glioma   Inflammatory Bowel Disease   Heart Failure  
1
HY-P99177 Enibarcimab
Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure.

Species: Human

Others  
Infection   Blood or Cardio-cerebrovascular Disease  
1
HY-P99891 Rovelizumab
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.

Species: Human

Integrin  
Blood or Cardio-cerebrovascular Disease  
1
HY-175324 MG-HuR2
MG-HuR2 is a molecular glue degrader targeting HuR (ELAVL1) with a Kd of 0.2018 μM. MG-HuR2 recruits the E3 ubiquitin ligase RNF126 and induces proteasome-dependent degradation of HuR. MG-HuR2 exhibits a unique biphasic degradation profile. MG-HuR2 reduces the expression of HuR and its downstream targets Bcl2/FOXQ1, inhibits breast cancer cell proliferation, enhances cytotoxicity and apoptosis (apoptosis), and suppresses the growth of 3D breast cancer tumor spheres. MG-HuR2 can be used in studies related to breast cancer and HuR-targeted protein degradation.
Molecular Glues   HuR   Apoptosis   Bcl-2 Family   E1/E2/E3 Enzyme  
Breast Cancer  
1
HY-P990209 Anti-Mouse IL-7Rα/CD127 Antibody (A7R34)
Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse IL-7Rα/CD127. Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) blocks IL-7 signaling. Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) can be used for the researches of cancer,infection, inflammation, immunology, cardiovascular and metabolic disease, such as abdominal aortic aneurysms, helicobacter felis-induced gastritis and diabetes.

Species: Mouse

Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
1
HY-147918 Anticancer agent 73
Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo.
DNA/RNA Synthesis  
Cancer  
1
HY-W329357 15:0 Lyso PC
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
Endogenous Metabolite  
Cardiovascular Disease  
1
HY-N0513 Loganic acid
Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active.
Free Radical Scavengers   Reactive Oxygen Species (ROS)   Phosphatase   NF-κB   Keap1-Nrf2  
Breast Cancer   Liver Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Parkinson's Disease   Obesity   Hypercholesterolemia   Osteoporosis   Lung Fibrosis   Ulcerative Colitis   Rheumatoid Arthritis  
1
HY-128700 Nicotinic acid mononucleotide
Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD+ biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD+ levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD+ levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease.
Endogenous Metabolite   Sirtuin  
Cancer   Huntington's Disease   Multiple Sclerosis  
1
HY-117832 Pyripyropene A
Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.

Source: filamentous fungi

Acyltransferase  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
1
HY-134601 KH-3
KH-3 is a potent RNA-binding protein Hu antigen R (HuR) inhibitor with an IC50 value of 0.35 μM. KH-3 has anti-proliferative activity. KH-3 suppresses breast cancer cell invasion as well as delays the initiation of lung colonies by disrupting HuR-FOXQ1 mRNA interaction.
HuR  
Breast Cancer  
1
HY-174228 I3IN-002
I3IN-002 is a small-molecule RNA-binding protein IGF2BP3 inhibitor with an IC50 value of approximately 2 μM in SEM cells. I3IN-002 interferes with interaction with m6 A-modified mRNAs, disrupting the stabilization of target genes (such as CDK6, MYC, and BCL2) to inhibit leukemic cell growth, induce cell cycle arrest, and promote apoptosis. I3IN-002 is promising for research of B-cell acute lymphoblastic leukemia.
Insulin Receptor   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation  
1
HY-113168 Butyrylcarnitine
Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer.
Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Cardiovascular Disease  
1
HY-10201S Sorafenib-d3
Sorafenib-d3 (Donafenib) is the deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Isotope-Labeled Compounds   Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
1
HY-W251428 Phosphatidylglycerols (egg) sodium salt
Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV).
Biochemical Assay Reagents  
1
HY-P9928 Alirocumab
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.

Species: Human

PCSK9   NOD-like Receptor (NLR)   Keap1-Nrf2   HMG Family   NF-κB   CX3CR1  
Inflammation or Immune System Disease   Atherosclerosis  
1
HY-W013812S2 Ethyl linoleate-d2
Ethyl linoleate-d2 (Linoleic Acid ethyl ester-d2; Mandenol-d2) is the deuterium labeled Ethyl linoleate (HY-W013812). Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-B0347S3 Lacidipine-13C4
Lacidipine-13C4 is 13C labeled Lacidipine (HY-B0347). Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI).
Calcium Channel   Apoptosis   Reactive Oxygen Species (ROS)   Caspase   Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-B0592S Trandolapril-d5
Trandolapril-d5 is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF).
Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-B0268AR Enoxacin hydrate (Standard)
Enoxacin (hydrate) (Standard) is the analytical standard of Enoxacin (hydrate). This product is intended for research and analytical applications. Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 μg/ml) and topoisomerase IV (IC50=26.5 μg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[4].
Reference Standards   Bacterial   DNA/RNA Synthesis   MicroRNA   Antibiotic  
Cancer   Infection  
/
HY-12879G IWP-4 (GMP)
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure.
Wnt   Casein Kinase  
Cancer   Alzheimer's Disease   Heart Failure  
/
HY-145581S Mitiperstat-d3
Mitiperstat-d3 (AZD4831-d3) is the deuterated -labeled Mitiperstat (HY-145581).Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.
Isotope-Labeled Compounds   Glutathione Peroxidase   Cytochrome P450  
Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Chronic Obstructive Pulmonary Disease  
/
HY-P1184 HNGF6A
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.
Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-124844 Azaphilone-9
Azaphilone-9 (AZA-9) is an inhibitor of HuR-ARE RNA interaction (IC50=1.2 μM) by binding RNA-binding protein Hu antigen R (HuR). The HuR-RNA interactions stabilize many oncogenic mRNAs in tumors. Thus Azaphilone-9 potentially inhibit cancer cell growth and progression.
HuR  
/
HY-P10577 RAG8 peptide
RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research.
Protease Activated Receptor (PAR)  
Blood or Cardio-cerebrovascular Disease  
/
HY-15407S3 Sacubitril-13C4
Sacubitril-13C4 (AHU-377-13C4) is a 13C-labeled version of Sacubitril (HY-15407). Sacubitril is an orally active inhibitor of neprilysin NEP (IC50=5 nM). Sacubitril is used in research on heart failure, hypertension and COVID-19.
Isotope-Labeled Compounds   Neprilysin  
Infection  
/
HY-172885 TRBP-IN-1
TRBP-IN-1 (Compound 13j) is an orally active TAR RNA binding protein 2 (TRBP) inhibitor (IC50: 12.72 μM). TRBP-IN-1 has significant anti-hepatocellular carcinoma (HCC) activity and can inhibit the proliferation and metastasis of HCC cells (HCCLM3 cells (IC50: 18.96 μM); SK-Hep-1 cells (IC50: 16.45 μM)). TRBP-IN-1 regulates miRNA biogenesis and inhibits oncogenic miRNA expression by targeting TRBP. TRBP-IN-1 induces apoptosis and pyroptosis in HCC cells by inhibiting the level of miRNA. TRBP-IN-1 can be used for targeted therapy research of HCC.
DNA/RNA Synthesis   MicroRNA   Apoptosis   Pyroptosis  
Cancer  
/
HY-P2687 Ularitide
Ularitide (Urodilatin), natriuretic peptide, is a vasodilator. Ularitide binds to and activates renal receptors. Ularitide also regulates renal dopamine metabolism Ularitide can be used in the research of heart failure.
Natriuretic Peptide Receptor (NPR)  
Blood or Cardio-cerebrovascular Disease  
/
HY-181666 Z971169476
Z971169476 is a sulfonamide-based protein-RNA interaction inhibitor targeting the KH34 region of insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2/IMP2).
Insulin Receptor  
Cancer  
/
HY-187270S [U-15N]-ApoE4
[U-15N]-ApoE4 is the 15N-labeled ApoE4. Apolipoprotein E4 (ApoE4) is a significant genetic risk factor for Alzheimer's disease and is closely linked to cardiovascular diseases-such as atherosclerosis-through its influence on lipid metabolism. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Atherosclerosis and Inflammation  
/
HY-P1306 Obestatin(rat)
Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities.
GHSR  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-174935B DBCO-PEG3400-NHS
DBCO-PEG3400-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material.
Biochemical Assay Reagents  
/
HY-112537S2 D-Glucose 6-phosphate-13C
D-Glucose 6-phosphate-13C is 13C labeled D-Glucose 6-phosphate (HY-112537). D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
Isotope-Labeled Compounds   mTOR   Endogenous Metabolite  
/
HY-N18772 Arthrospira platensis extract
Arthrospira platensis extract is a nutrient-rich and bioactive substance derived from spirulina (Arthrospira platensis) that enhances the immune system, has antioxidant and anti-inflammatory effects, and has potential cardiovascular health benefits.
Others  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-120521 Urodilatin
Urodilatin is an analogue of ANF-(99-126). Urodilatin is a diuretic-natriuretic regulatory peptide. Urodilatin can be used for research of acute renal failure, congestive heart failure, and bronchial asthma, etc.
Natriuretic Peptide Receptor (NPR)  
Neurological, Eye or Ear Disease  
/
HY-N15743 Anti-Heart Failure Agent 2
Anti-Heart Failure Agent 2 (Compound 1) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 2 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 2 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 2 is promising for research of heart failure.
NO Synthase  
Blood or Cardio-cerebrovascular Disease  
/
HY-W744298 Trandolapril-d3
Trandolapril-d3 is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-17380S (S)-Timolol-d9 maleate
(S)-Timolol-d9 (maleate) is deuterium labeled (S)-Timolol (Maleate). (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
Isotope-Labeled Compounds   Adrenergic Receptor  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P5762A Phoenixin-14 TFA
Phoenixin-14 (PNX-14) TFA is an endogenous neuropeptide with multiple biological activities, and serves as the endogenous ligand of GPR173. Phoenixin-14 TFA reduces ROS production by inhibiting the HMGB1/TLR4/MyD88/NF-κB signaling axis, thereby exerting antioxidant and mitochondrial protective effects. Phoenixin-14 TFA inhibits FOXO3 phosphorylation by upregulating SIRT3 expression, suppresses apoptosis, and improves myocardial systolic/diastolic function. Phoenixin-14 TFA resists ferroptosis by activating the ATF4/SLC7A11/GPX4 axis; it activates ERK1/2 phosphorylation via GPR173. Phoenixin-14 TFA can be used in researches on neuroprotection, diabetes, cardiomyopathy, reproductive protection and so on.
Reactive Oxygen Species (ROS)   Orphan GPCR   ERK   FOXO   MyD88   NF-κB   Ferroptosis   Sirtuin   PKA   Apoptosis   Glutathione Peroxidase   Toll-like Receptor (TLR)   Akt  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-187272S [U-15N]-ApoB
[U-15N]-ApoB is the 15N-labeled ApoB. Apolipoprotein B (ApoB) levels are a critical parameter for assessing cardiovascular diseases, such as atherosclerosis. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Atherosclerosis and Inflammation  
/
HY-N20270 Trichosanthis fructus extract
Trichosanthis fructus extract is an extract of Trichosanthis fructus that can be used in research on angina pectoris, heart failure, myocardial infarction, pulmonary heart disease, and cerebral ischemia.
Others  
Pain  
/
HY-N19029 Vernodalin
Vernodalin is an orally active, cytotoxic sesquiterpene lactone with a Kd value of 9.55 μM for p38 MAPK. Vernodalin downregulates the expression of phosphorylated ERK, JNK, AKT, PI3K, mTOR, p38MAPK, FAK, MMP-2, MMP-9, and uPA, while upregulates the expression of TIMP-1 and TIMP-2. Vernodalin increases ROS production, upregulates the expression of Bax and caspase 3, downregulates the expression of Bcl-2, and induces apoptosis (apoptosis), oxidative stress response and cell cycle arrest. Vernodalin inhibits the proliferation, adhesion and metastasis of cancer cells. Vernodalin enhances the activity of VEGF-B, AMPK and eNOS signaling pathways. Vernodalin alleviates myocardial injury and restores hemodynamic parameters. Vernodalin inhibits the growth of Trypanosoma brucei rhodesiense. Vernodalin can be used in research related to various cancers including gastric cancer, colorectal cancer and lung cancer, as well as African human trypanosomiasis and myocardial infarction.
p38 MAPK   PERK   JNK   Akt   PI3K   mTOR   FAK   MMP   PAI-1   Reactive Oxygen Species (ROS)   Caspase   Bcl-2 Family   Apoptosis   VEGFR   AMPK   Parasite  
Lung Cancer   Colorectal Cancer   Gastric Cancer   Trypanosome Infection   Myocardial Infarction  
/
HY-D1409 DMTr-4'-F-U-CED-TBDMS phosphoramidite
DMTr-4'-F-U-CED-TBDMS phosphoramidite (DMTr-4'-F-uridine-CED-TBDMS phosphoramidite), a dye reagent for oligonucleotide labeling, can be used for the research of applications in RNA therapeutics, RNA aptamers, and ribozymes for elucidating RNA structure. DMTr-4'-F-U-CED-TBDMS phosphoramidite represents a probe with wide utility for elucidation of RNA structure.
DNA Stain   Phosphoramidites  
Blood or Cardio-cerebrovascular Disease  
/
HY-D3197 CDg16
CDg16 is a selective fluorescent dye targeting SLC18B1 (λabs/λem=458/544 nm) that is actively transported into lysosomal vesicles of activated macrophages independent of the endocytic pathway. CDg16 enables highly specific vesicle localization in live cells. CDg16 exhibits no cytotoxicity and accurately distinguishes activated M1 and M2 subsets from different origins. CDg16 shows low background staining in non-activated cells and normal organs, making it suitable for time-lapse imaging. In preclinical animal models of inflammatory sites, atherosclerotic plaques and liver inflammation, CDg16 allows visualization of activated macrophages. CDg16 can be used to study inflammation-related diseases and atherosclerosis.
Fluorescent Dye  
Atherosclerosis and Inflammation  
/
HY-114977S Avenanthramide A-d4
Avenanthramide A-d4 is the deuterium labeled Avenanthramide A (HY-114977). Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a KD of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis.
Isotope-Labeled Compounds   Reactive Oxygen Species (ROS)   DNA/RNA Synthesis   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-P2682 MMP-8/MMP-26 Fluorogenic substrate
MMP-8/MMP-26 Fluorogenic substrate (DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg) is a matrix metalloproteinase-8 (MMP-8) fluorogenic substrate. MMP-8/MMP-26 Fluorogenic substrate can be used for the research of atherosclerosis, pulmonary fibrosis, and sepsis.
MMP  
Metabolic or Endocrine Disease  
/
HY-N15744 Anti-Heart Failure Agent 3
Anti-Heart Failure Agent 3 (Compound 2) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 3 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 3 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 3 is promising for research of heart failure.
NO Synthase  
Blood or Cardio-cerebrovascular Disease  
/
HY-173274 CB039
CB039 is a RBM39 molecular glue degrader with an IC50 of 36.7 nM against HCT-116 cells. CB039 induces RBM39 degradation in a dose- and time-dependent manner. This process depends on the Cullin-RING E3 ubiquitin ligase complex (CRL) and proteasome, and promotes the recruitment of RBM39 to the DCAF15-DDB1 complex with an IC50 of 594 nM. CB039 causes abnormal RNA splicing, reduces CEP192 protein levels, induces G2/M phase cell cycle arrest and mitotic spindle disorder. CB039 can be used in studies on RBM39-targeted protein degradation and colorectal cancer-related mechanisms.
Molecular Glues  
Colorectal Cancer  
/
HY-D3170 C-HBrO-GGT
C-HBrO-GGT is a dual-target fluorescent indicator with specificity for γ-glutamyl transpeptidase (GGT) and hypobromous acid (HBrO). C-HBrO-GGT acts as a substrate for GGT and HBrO, undergoing enzymatic or chemical modification to trigger channel-specific fluorescence, with sequential activation requiring initial GGT hydrolysis. C-HBrO-GGT enables simultaneous in vitro and in vivo fluorescence detection of GGT and HBrO. C-HBrO-GGT identifies mature atherosclerotic plaque positions and provides early warning of plaque formation before visual or classical immunofluorescent detection. C-HBrO-GGT can be used for the research of atherosclerosis (Ex/Em = 370 nm/500 nm).
Fluorescent Dye   γ-Glutamyl Transferase (GGT)  
Atherosclerosis  
/
HY-B0251S Eplerenone-d3
Eplerenone-d3 is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch.
Isotope-Labeled Compounds   Mineralocorticoid Receptor   Endogenous Metabolite  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11836 IL-1β-IN-3
IL-1β-IN-3 is a IL-1β inhibitor with an IC50 value of 0.021 nM. IL-1β-IN-3 can be used in the research of atherosclerosis and inflammatory diseases.
Interleukin Related  
Atherosclerosis and Inflammation  
/
HY-P991895 PLG-101
PLG-101 is a human anti-CD8 antibody. PLG-101 can be used in research on acute myocardial infarction .

Species: Human

Transmembrane Glycoprotein  
Myocardial Infarction  
/
HY-N15745 Anti-Heart Failure Agent 4
Anti-Heart Failure Agent 4 (Compound 3) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 4 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 4 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 4 is promising for research of heart failure.
NO Synthase  
Blood or Cardio-cerebrovascular Disease  
/
HY-174935C DBCO-PEG5000-NHS
DBCO-PEG5000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material.
Biochemical Assay Reagents  
/
HY-107965 Safflower oil (from Carthamus tinctorius seed)
Safflower oil (from Carthamus tinctorius seed) is rich in unsaturated fatty acids such as linoleic acid and oleic acid, as well as tocopherols and phenolic compounds, and exhibits antioxidant, anti-aging and blood lipid-regulating effects. Safflower oil (from Carthamus tinctorius seed) inhibits the activities of collagenase and elastase, and exerts antioxidant activity by scavenging free radicals. Linoleic acid in safflower oil (from Carthamus tinctorius seed) reduces blood cholesterol levels. Safflower oil (from Carthamus tinctorius seed) can be applied to research in fields such as skin aging, atherosclerosis, edible oil processing and industrial raw material development.
Free Radical Scavengers  
Antioxidant Agent   Cellular Senescence  
/
HY-101112 Okicenone
Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation.

Source: Streptomyces

HuR  
Inflammation or Immune System Disease  
/
HY-174935D DBCO-PEG10000-NHS
DBCO-PEG10000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material.
Biochemical Assay Reagents  
/
HY-P1129 AR-M1896
AR-M1896 is a GalR2 selective agonist with a binding IC50 of 1.76 nM for rat GalR2. AR-M1896 can be used for the research of acute myocardial infarction and neuropathic pain.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
/
HY-P991412 NI-301
NI-301 is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research.

Species: Human

Transthyretin (TTR)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P11351 Precursor-HhH
Precursor-HhH is a nucleic acid-binding peptide capable of non-specific interactions with RNA and double-stranded DNA (dsDNA). Precursor-HhH is promising for research of nucleic acid-targeted therapeutics.
DNA/RNA Synthesis  
Cancer  
/
HY-D1408 DMTr-4'-Me-U-CED-TBDMS phosphoramidite
DMTr-4'-Me-U-CED-TBDMS phosphoramidite (DMTr-4'-Methyluridine-CED-TBDMS phosphoramidite), a dye reagent for oligonucleotide labeling, can be used for the research of applications in RNA therapeutics, RNA aptamers, and ribozymes for elucidating RNA structure. DMTr-4'-Me-U-CED-TBDMS phosphoramidite represents a probe with wide utility for elucidation of RNA structure.
DNA Stain   Phosphoramidites  
Blood or Cardio-cerebrovascular Disease  
/
HY-113301S Hexacosanoic acid-d4
Hexacosanoic acid-d4 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P11041 VS-IP1
VS-IP1 is an interfering peptide that blocks viperin-mediated STAT1 degradation, thereby preventing coxsackievirus B3 (CVB3)-induced acute heart failure (AHF).
STAT  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991574 MEDI-5884
MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC50 of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its Kd values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.

Species: Human

Lipase   Apolipoprotein  
Atherosclerosis and Inflammation   Atherosclerosis  
/
HY-B0209S Metolazone-d7
Metolazone-d7 is deuterium labeled Metolazone. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P1184A HNGF6A TFA
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-103248R Toyocamycin (Standard)
DL-Aspartic acid (Standard) is the analytical standard of DL-Aspartic acid. This product is intended for research and analytical applications. DL-Aspartic acid (DL-Asp-OH) is a kind of biological materials or organic compounds that are widely used in life science research.
Reference Standards   IRE1   Fungal   Antibiotic   Apoptosis   CDK  
Cancer   Infection  
/
HY-P992023 APX002
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis.

Species: Human

Interleukin Related  
Autoimmune Disease  
/
HY-P11698 Guanidino-G-Clamp-PNA
Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis.
DNA Alkylator/Crosslinker   Transthyretin (TTR)  
Diffuse Large B-cell Lymphoma  
/
HY-135746S OR-1896-d3
OR-1896-d3 is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation.
Isotope-Labeled Compounds   Potassium Channel   Apoptosis   Phosphodiesterase (PDE)   Drug Metabolite  
/
HY-P4890 Relaxin H3 (human)
Relaxin H3 (human) is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
RXFP Receptor   Reactive Oxygen Species (ROS)   Pyroptosis   Caspase   Interleukin Related   TGF-beta/Smad   AMPK   Apoptosis  
Autoimmune Disease   Kidney Stones  
/
HY-N21583 Dracoflavan B2
Dracoflavan B2 is an allosteric activator of pyruvate carboxylase (PC) that enhances Oxaloacetic acid (HY-W010382) production by inducing conformational changes in the BCCP domain, restores mitochondrial function, and improves metabolism, while also exhibiting anti-inflammatory activity. Dracoflavan B2 can be used for research on myocardial infarction.
Pyruvate Carboxylase (PC)  
Myocardial Infarction  
/
HY-P2632 RAD16-I
RAD16-I (RADA16) is a non-directed self-assembling peptide hydrogel. Under physiological conditions, RAD16-I spontaneously forms a three-dimensional nanofiber network that mimics the extracellular matrix, and possesses excellent properties such as high water content, biocompatibility and degradability. RAD16-I serves as an ideal scaffold for three-dimensional cell culture. RAD16-I not only maintains cell viability and induces self-organization, but also supports cell adhesion, proliferation, differentiation and insulin secretion, effectively stabilizes islet clusters and promotes directed differentiation of the cardiac lineage. RAD16-I can construct a cell-friendly nano-microenvironment for research related to diseases such as myocardial infarction and diabetes.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-W240322 PSF-IN-1
PSF-IN-1 (Compound No.10-3) is a RNA-binding protein (PSF) inhibitor and can effectively inhibit the PSF-RNA interaction (IC50: 2.2 pM). PSF-IN-1 can increase histone acetylation, inhibit tumor cell proliferation and induce apoptosis. PSF-IN-1 has antitumor activity.
Apoptosis  
/
HY-P991947 ELB041
ELB041 (AFS98) is a rat monoclonal anti-murine c-fms antibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis.

Species: Human

c-Fms  
Atherosclerosis and Inflammation  
/
HY-113071AR Mevalonic acid lithium salt (Standard)
Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure.
Reference Standards   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-A0115S2 Ramiprilat-d4 hydrochloride
Ramiprilat-d4 hydrochloride is deuterated labeled Ramiprilat (HY-A0115). Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research.
Endogenous Metabolite   Drug Metabolite   Angiotensin-converting Enzyme (ACE)   Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-A0154R Deslanoside (Standard)
Deslanoside (Standard) is the analytical standard of Deslanoside. This product is intended for research and analytical applications. Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
Reference Standards   Na+/K+ ATPase   Drug Metabolite  
Blood or Cardio-cerebrovascular Disease  
/
HY-P0119S Lixisenatide (Leu-13C6,15N) TFA
Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
Isotope-Labeled Compounds   GLP Receptor   Akt   MEK   Apoptosis   Reactive Oxygen Species (ROS)   MMP  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-B0202S3 Irbesartan-d7
Irbesartan-d7 is deuterated labeled Irbesartan (HY-B0202). Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
Apoptosis   Angiotensin Receptor   Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-D3598 CCR2 ligand-2
CCR2 ligand-2 is a small-molecule fluorescent ligand targeting the intracellular allosteric binding site (IABS) of CCR2, with a Kd value of 266 nM for membrane-based binding affinity and a Kd value of 114 nM for binding affinity in live cells. CCR2 ligand-2 enables non-isotopic, high-throughput cell-free and cell-based NanoBRET binding assays. CCR2 ligand-2 serves as a tool for fragment-based screening strategies.
CCR  
/
HY-18206S1 (S)-Lisinopril-d5 sodium
(S)-Lisinopril-d5 (sodium) (MK-521-d5 (sodium)) is deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-17494S1 Timolol-d9 maleate
Timolol-d9 (maleate) is deuterium labeled Timolol. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
Isotope-Labeled Compounds   Adrenergic Receptor  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P992108 Efadirelaxin alfa
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure.

Species: Human

RXFP Receptor   Akt   NO Synthase   VEGFR  
Heart Failure  
/
HY-N2037R Higenamine (Standard)
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases.
Reference Standards   MAP3K   MDM-2/p53   Adrenergic Receptor   ROS Kinase   Apoptosis  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease   Bacterial Infection  
/
HY-100713S Temocapril-d5
Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P990822 Anti-Mouse TIM-1/CD365 Antibody (3D10)
Anti-Mouse TIM-1/CD365 Antibody (3D10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can block mouse T cell immunoglobulin and mucin domain 1 (TIM-1) also known as CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can be used for the researches of inflammation, immunology and cardiovascular disease, such as graft-versus-host disease (GVHD), airway inflammation and atherosclerosis.

Species: Mouse

Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P990252 Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma.

Species: Mouse

Notch   Interleukin Related   NF-κB   VEGFR   FGFR   NO Synthase  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-174935 DBCO-PEG1000-NHS
DBCO-PEG1000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material.
Biochemical Assay Reagents  
/
HY-B0202AS Irbesartan-d7 hydrochloride
Irbesartan-d7 hydrochloride is deuterated labeled Irbesartan hydrochloride (HY-B0202A). Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
Apoptosis   Angiotensin Receptor   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-B0268S2 Enoxacin-d8 hydrate
Enoxacin-d8 (hydrate) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 μg/ml) and topoisomerase IV (IC50=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
Isotope-Labeled Compounds   DNA/RNA Synthesis   MicroRNA   Antibiotic   Bacterial  
Cancer   Infection  
/
HY-B0592S2 rac-Trandolapril-d5
rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-W654009 Loxoprofen-d3
Loxoprofen-d3 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity.
Isotope-Labeled Compounds   COX  
Inflammation or Immune System Disease  
/
HY-W759845 Aficamten-d3
Aficamten-d3 (CK-274-d3) is deuterium labeled Aficamten. Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).
Isotope-Labeled Compounds   Myosin  
Blood or Cardio-cerebrovascular Disease  
/
HY-174590 Human LIN28A mRNA
Human Lin-28 homolog A (LIN28A) mRNA encodes a LIN-28 family RNA-binding protein that acts as a posttranscriptional regulator of genes involved in developmental timing and self-renewal in embryonic stem cells. LIN28A functions through direct interaction with target mRNAs and by disrupting the maturation of certain miRNAs involved in embryonic development.
mRNA  
Cancer  
/
HY-18204S Valsartan-d9
Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
Angiotensin Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P3429 SAMβA
SAMβA is conjugated to the cell permeable peptide TAT47-57. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
PKC  
Blood or Cardio-cerebrovascular Disease  
/
HY-P3557A Mibenratide TFA
Mibenratide TFA, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide TFA can be used for heart failure research.
Adrenergic Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-DY1088 Fluorescein-5-maleimide (solution)
Fluorescein-5-maleimide (solution) (N-(5-Fluoresceinyl)maleimide (solution)) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiac myosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm.

Solvent and concentration: DMSO: 10 mM
Fluorescent Dye  
/
HY-P4890A Relaxin H3 (human) TFA
Relaxin H3 (human) TFA is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) TFA acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) TFA inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) TFA activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) TFA can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
RXFP Receptor   Reactive Oxygen Species (ROS)   Pyroptosis   Caspase   Interleukin Related   TGF-beta/Smad   AMPK   Apoptosis  
Autoimmune Disease   Kidney Stones  
/
HY-P5117 TAT-CIRP
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice.
Toll-like Receptor (TLR)  
Neurological, Eye or Ear Disease  
/
HY-P99886 Pexelizumab
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.

Species: Human

Complement System   Apoptosis  
Blood or Cardio-cerebrovascular Disease   Ischemia-Reperfusion Injury  
/
HY-174935A DBCO-PEG2000-NHS
DBCO-PEG2000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material.
Biochemical Assay Reagents  
/
HY-122970 1,2-Dihydrotanshinone
1,2-Dihydrotanshinone (1,2-Dihydrotanshinquinone) is an abietane diterpene. 1,2-Dihydrotanshinone inhibits the formation of the pathogenic complex formed between (CUG)n-RNA and the splicing-factor muscleblind-like 1 (MBNL1). 1,2-Dihydrotanshinone can be used for the research of myotonic dystrophy type 1.
DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-105168 TAK 044
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage.
Endothelin Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-N0264R Ligustrazine (Standard)
Ligustrazine (Standard) (Chuanxiongzine (Standard)) is the analytical standard of Ligustrazine (HY-N0264). This product is intended for research and analytical applications. Ligustrazine (Chuanxiongzine) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.
Reference Standards   Reactive Oxygen Species (ROS)   Akt   NO Synthase   Aminotransferases (Transaminases)  
Cerebrovascular Disease   Lipid Metabolism   Ischemia-Reperfusion Injury   Atherosclerosis and Inflammation  
/
HY-B0268S1 Enoxacin-d8 hydrochloride
Enoxacin-d8 (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 μg/ml) and topoisomerase IV (IC50=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
Isotope-Labeled Compounds   Bacterial   DNA/RNA Synthesis   MicroRNA   Antibiotic  
Cancer   Infection  
/
HY-113301S1 Hexacosanoic acid-d4-1
Hexacosanoic acid-d4-11 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-18206S Lisinopril-d5
Lisinopril-d5 is the deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-B1409S Isosorbide dinitrate-13C6
Isosorbide dinitrate-13C6 is the 13C labeled Isosorbide dinitrate. Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI).
NO Synthase  
Blood or Cardio-cerebrovascular Disease  
/
HY-17494S (Rac)-Timolol-d5 maleate
rac Timolol-d5 (maleate) is a labelled racemic (S)-Timolol maleate. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
Isotope-Labeled Compounds   Adrenergic Receptor  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P3557 Mibenratide
Mibenratide, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide can be used for heart failure research.
Adrenergic Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P3678 Neuropeptide Y (18-36) (porcine)
Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P991333 GSK-315234
GSK-315234 is a human IgG1 monoclonal antibody (mAb) targeting OSM . GSK-315234 can be used in the study of atherosclerosis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-A0143S Dihomo-γ-linolenic acid-d6
Dihomo-γ-linolenic acid-d6 (DGLA-d6) is the deuterium labeled Dihomo-γ-linolenic acid. Dihomo-γ-linolenic acid (all-cis-8,11,14-Eicosatrienoic acid) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system.
Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P6437A Drp1 peptide inhibitor P110 TFA
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.
Dynamin  
Huntington's Disease   Myocardial Infarction  
/
HY-N7177 Hydroxytanshinone IIA
Hydroxytanshinone IIA is a hydrolytic metabolite of Tanshinone IIA (HY-N0135). Tanshinone IIA inhibits angiogenesis by targeting the protein kinase domain of VEGF/VEGFR2. Hydroxytanshinone IIA exhibits antioxidant and anti-inflammatory activities. Hydroxytanshinone IIA can be used in studies of angina pectoris and myocardial infarction.
VEGFR   Drug Metabolite  
Antioxidant Agent   Angina   Myocardial Infarction  
/
HY-P99645 Goflikicept
Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI).
Interleukin Related  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-B0573BS Propranolol-d7
Propranolol-d7 is the deuterium labeled Propranolol. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99946 Erlizumab
Erlizumab (rhuMAb) is a monoclonal antibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction.

Species: Human

Integrin  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Breast Cancer  
/
HY-P6437 Drp1 peptide inhibitor P110
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.
Dynamin  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-N1403 Tigogenin
Tigogenin is a steroidal sapogenins. Tigogenin can inhibit adipocytic differentiation and induce osteoblastic differentiation in mouse bone marrow stromal cells. Tigogenin can inhibit cells proliferation and induce apoptosis. Tigogenin can be used for the researches of cancer, inflammation, immunology, metabolic and cardiovascular disease, such as mammary gland carcinoma, rheumatoid arthritis, osteoporosis and atherosclerosis.
Apoptosis  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Rheumatoid Arthritis  
/
HY-B0573S1 Propranolol-d7 (ring-d7)
Propranolol-d7 (ring-d7) is the deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-138652 L-Histidine benzyl ester (bistosylate)
L-Histidine benzyl ester bistosylate is a modified amino acid. L-Histidine benzyl ester bistosylate can be used in peptide synthesis and RNA-related research.
Bacterial  
Bacterial Infection  
/
HY-W087008 7-Hydroxyflavanone
7-Hydroxyflavanone is an aromatase (CYP19) activity inhibitor found in plants with an IC50 of 65 μM, and it also possesses 20S proteasome inhibitory activity. 7-Hydroxyflavanone significantly inhibits primary humoral immunity to SRBC in mice and weakly suppresses DTH. 7-Hydroxyflavanone 1 attenuates Doxorubicin (HY-15142A)-induced oxidative stress, IL-6 inflammation, mitochondrial dysfunction, caspase 3/7 activation, apoptosis, and necrosis, and upregulates the PGC-1α/pAMPK/Beclin-1 autophagy-related pathway. 7-Hydroxyflavanone is extensively metabolized by various fungi, undergoing multiple structural modifications. 7-Hydroxyflavanone can be used in research related to Doxorubicin-induced cardiomyopathy and immune system diseases.
Cytochrome P450   Interleukin Related   Caspase   Apoptosis   PGC-1α   AMPK   Beclin1  
Inflammation or Immune System Disease   Cardiomyopathy  
/
HY-P3429A SAMβA TFA
SAMβA TFA is a rationally designed selective antagonist of Mfn1-βIIPKC association and can bind to TAT (HY-P0281). SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
PKC  
Blood or Cardio-cerebrovascular Disease  
/
HY-124648 SMN-C2
SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research.
DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-P10728 B7-33
B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis.
RXFP Receptor   ERK  
Inflammation or Immune System Disease   Cardiovascular Disease  
/
HY-W011927R 4,4'-Sulfonyldiphenol (Standard)
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) (Standard) is the analytical standard of 4,4'-Sulfonyldiphenol (HY-W011927). This product is intended for research and analytical applications. 4,4'-Sulfonyldiphenol, a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Reference Standards   Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-N11222 Nonanoylcarnitine
Nonanoylcarnitine is a metabolite associated with chronic environmental exposure to polycyclic aromatic hydrocarbons (PAH) and fragmented QRS waves in acute myocardial infarction. Nonanoylcarnitine can be used as a potential biomarker for the metabolic outcome of PAH exposure and the prognosis of acute myocardial infarction.
Endogenous Metabolite  
Cancer   Cardiovascular Disease  
/
HY-B0573S Propranolol-d7 hydrochloride
Propranolol-d7 (hydrochloride) is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-W012340 H-HomoArg-OH hydrochloride
H-HomoArg-OH hydrochloride (L-Homoarginine hydrochloride) is an orally active endogenous non-protein amino acid. H-HomoArg-OH hydrochloride acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y+-type transporters (system y+). H-HomoArg-OH hydrochloride increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HomoArg-OH hydrochloride can be used in studies related to diabetes and cardiomyopathy.
Endogenous Metabolite   Monocarboxylate Transporter   Phosphatase  
Glucose Metabolism   Cardiomyopathy  
/
HY-P991222 AMG-529
AMG-529 is a humanized monoclonal antibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases.

Species: Human

Phosphatase  
Blood or Cardio-cerebrovascular Disease  
/
HY-NP192 Sericin
Sericin is an orally active globular protein produced by silkworm cocoons. Sericin inhibits the expression of COX2, iNOS, TLR4, MAPK and NF-κB; reduces the levels of IL-18, IL-1 and CCL2; antagonizes the activity of AChE; and downregulates the expression of Bcl-2. Sericin enhances the PI3K/AKT-mediated insulin signaling pathway. Sericin inhibits the activity of tyrosinase (Tyrosinase), scavenges ROS, chelates metal ions, and increases the levels of antioxidant enzymes. Sericin induces apoptosis and arrests the cell cycle. Sericin exhibits antibacterial, moisturizing, cardioprotective and anticoagulant properties. Sericin can be used in research related to type 2 diabetes, hyperlipidemia, obesity, Alzheimer's disease, colon cancer, peripheral nerve injury and ischemic myocardial infarction.
Reactive Oxygen Species (ROS)   Bacterial   COX   NO Synthase   Toll-like Receptor (TLR)   p38 MAPK   NF-κB   Interleukin Related   Cholinesterase (ChE)   Bcl-2 Family   Tyrosinase   PI3K   Akt  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N3431 Kaempferol-7-O-rhamnoside
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure.
AMPK   PD-1/PD-L1   FXR   Reactive Oxygen Species (ROS)  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity  
/
HY-122917 Danshenol A
Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research.
Aldose Reductase   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P99793 Orticumab
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.

Species: Human

LDLR  
Inflammation or Immune System Disease  
/
HY-176471 IGF2BP3-IN-1
IGF2BP3-IN-1 (Compound I3IN-122) is an IGF2BP3 (a RNA binding protein) inhibitor (IC50: > 50 μM), and can be used for cancer research.
Insulin Receptor  
Cancer  
/
HY-119734 Gossypolone
Gossypolone is an RNA-binding protein Musashi-1 inhibitor with a Ki of 12 nM. Gossypolone disrupts the Musashi-numb RNA interaction and directly binds to the RBD1 of MSI1 protein. Gossypolone can be used for the research of cancer.
DNA/RNA Synthesis  
Cancer  
/
HY-P1435 NoxA1ds
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors.
NADPH Oxidase  
Blood or Cardio-cerebrovascular Disease  
/
HY-125972 zr17-2
zr17-2 is a cold inducible RNA-binding protein (CIRBP) agonist. zr17-2 has anti-inflammatory and anti-oxidant and can be used for the study of myocardial infarction. zr17-2 is a hypothermia mimetic molecule that reduces oxidative stress-induced retinal cell death.
Keap1-Nrf2   Heme Oxygenase (HO)  
Pain   Parkinson's Disease   Myocardial Infarction  
/
HY-P990951 Vixticibart
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension.

Species: Human

Natriuretic Peptide Receptor (NPR)  
Hypertension   Heart Failure  
/
HY-NP005 Avidin, chiken egg white
Avidin, chicken egg white is a protein found in chicken egg white and a reagent for blocking endogenous biotinylated proteins in RNA pull-down assays.
Biochemical Assay Reagents  
/
HY-113270 Actinine
Actinine is a metabolic and pro-atherogenic intermediate with oral activity. Actinine acts as a substrate for the yeaW/X microbial enzyme complex to generate trimethylamine (TMA). Actinine accelerates atherosclerosis development in a gut microbe-dependent manner. Actinine can be used for the research of atherosclerosis.

Source: Porphyra yezoensis

Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-163759 HuR degrader 2
HuR degrader 2 is a molecular glue degrader targeting HuR (ELAVL1). HuR degrader 2 degrades the RNA-binding protein HuR. HuR degrader 2 can be used for the research of pancreatic ductal adenocarcinoma.
Molecular Glues   HuR  
Pancreatic Ductal Adenocarcinoma  
/
HY-W008385 H-HoArg-OH
H-HomoArg-OH (L-Homoarginine) is an orally active endogenous non-protein amino acid. H-HomoArg-OH acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y+-type transporters (system y+). H-HomoArg-OH increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HomoArg-OH can be used in studies related to diabetes and cardiomyopathy.
Endogenous Metabolite   Monocarboxylate Transporter   Phosphatase  
Glucose Metabolism   Cardiomyopathy  
/
HY-P1615 Cenupatide
Cenupatide (UPARANT) is a uPAR and FPR antagonist with anti-angiogenic, anti-inflammatory, and vascular barrier regulatory activities, as well as high stability and resistance to enzymatic degradation in blood/plasma. Cenupatide blocks the uPAR-FPR interaction, reduces VEGF-induced phosphorylation levels of AKT, VEGFR-2, STAT3, JNK, p38 MAPK, ERK1/2, and NF-κB p65, and inhibits αvβ3 integrin activation. Cenupatide suppresses endothelial cell migration, invasion, tube formation, and angiogenic signaling pathways, restores tight junctions and blood-retinal barrier integrity, reduces pro-inflammatory marker levels, and inhibits apoptosis. Cenupatide reduces retinal neovascularization, renal fibrosis, and vascular leakage, and restores visual function in preclinical models. Cenupatide is applicable to research related to retinopathy, diabetic complications, ocular diseases, cancer, and inflammatory diseases.
Transmembrane Glycoprotein   Formyl Peptide Receptor (FPR)   VEGFR   Akt   STAT   JNK   p38 MAPK   ERK   NF-κB   Apoptosis   Integrin  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Glucose Metabolism   Retinopathy  
/
HY-P10554 Myhc-α(334–352)
Myhc-α(334–352) is a sequence fragment of amino acid residues 334 to 352 of cardiac myosin heavy chain α. Myhc-α(334–352) is an immunodominant epitope that can induce autoimmune reactions in A/J mice, leading to the occurrence of myocarditis. Myhc-α(334–352) can be used to study the autoimmune pathways of myocarditis and dilated cardiomyopathy.
Others  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P10580 Vasculotide
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.
Tie   PI3K   Akt   Cadherin   Claudin  
Infection   Blood or Cardio-cerebrovascular Disease   Skin Inflammation  
/
HY-W013812 Ethyl linoleate
Ethyl linoleate (Linoleic Acid ethyl ester) is an orally active unsaturated fatty acid. Ethyl linoleate inhibits the Akt/GSK3β/β-catenin signaling pathway and the activation of NF-κB. Ethyl linoleate induces heme oxygenase-1 and inhibits tyrosinase. Ethyl linoleate has whitening and anti-inflammatory effects. Ethyl linoleate promotes compound absorption. Ethyl linoleate has a significant influence on atherosclerosis. Ethyl linoleate is used in the research of inflammatory diseases. Ethyl linoleate can be used in cosmetics
Tyrosinase   β-catenin   GSK-3   Akt   Biochemical Assay Reagents   NF-κB   Heme Oxygenase (HO)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-145746 Sulfo-Cy5 azide
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm).
Fluorescent Dye   PD-1/PD-L1  
Breast Cancer   Atherosclerosis and Inflammation  
/
HY-P990730 Cabotamig
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers.

Species: Human

CD3   Cadherin  
Gastric Cancer  
/
HY-P99047 Simtuzumab
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis.

Species: Human

Monoamine Oxidase  
Cardiomyopathy   Lung Fibrosis  
/
HY-NP007 Myoglobin
Myoglobin is an oxygen-binding heme protein. Myoglobin scavenges ROS via its peroxidase activity, and binds to and inactivates NO in the heart and oxidative skeletal muscle. Myoglobin stores, buffers and facilitates intracellular oxygen diffusion, maintains aerobic metabolism under hypoxic/anoxic conditions, and provides oxygen supply support for mitochondria. Myoglobin alleviates oxidative stress, protects cardiac function and affects cardiac redox pathways. Myoglobin can be used in studies related to ischemia-reperfusion injury, oxidative stress-induced cardiac dysfunction and acute myocardial infarction.
Reactive Oxygen Species (ROS)   NO Synthase  
Ischemia-Reperfusion Injury   Myocardial Infarction  
/
HY-P5960 PTBP1-RNA-binding inhibitor P6 TFA
PTBP1-RNA-binding inhibitor (PTBP1 α3-helix derived peptide) P6 TFA is a cell-permeable PTBP1 inhibitor. PTBP1-RNA-binding inhibitor P6 TFA binds to the α3 helix binding site of the PTBP1 RRM1 domain, and disrupts the synergistic RNA-binding effect of the RRM1 and RRM2 domains of PTBP1. PTBP1-RNA-binding inhibitor P6 (TFA) regulates the regulatory pattern of PTBP1-related alternative splicing events, and thus exhibits anticancer potential.
DNA/RNA Synthesis  
Cancer  
/
HY-P990363 Anti-CDH17/Cadherin-17 Antibody (PTA001_A4)
Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a CHO-expressed human-mouse chimeric antibody targeting CDH17/Cadherin-17. Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) contains an IgG1-type heavy chain and a kappa-type light chain, with a predicted molecular weight (MW) of 149.12 kDa.

Species: Human

Cadherin  
Cancer  
/
HY-P99139 Anti-Mouse IL-1b Antibody (B122)
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.

Species: Mouse

Interleukin Related   Reactive Oxygen Species (ROS)   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Glioma  
/
HY-P99125 Anti-Mouse CD16/CD32 Antibody (2.4G2)
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.

Species: Mouse

Fc Receptor (FcR)  
Autoimmune Disease   Atherosclerosis  
/
HY-125863 Glucose-6-phosphate dehydrogenase, Microorganism
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy.
Biochemical Assay Reagents  
Cancer   Glucose Metabolism  
/
HY-A0154 Deslanoside
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
Na+/K+ ATPase   Drug Metabolite  
Cardiovascular Disease  
/
HY-P5282 ApoA-I mimetic peptide
ApoA-I mimetic peptide is an ApoA-I mimetic peptide. ApoA-I mimetic peptide has good phosphatidylcholine: cholesterol acyltransferase (LCAT) activation activity. ApoA-I mimetic peptide can be used to synthesize peptide/lipid complexes. ApoA-I mimetic peptide can be used in atherosclerosis research. (The sequence is: PVLDLFRELLNELLEALKQKLK).
Acyltransferase  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-W011927 4,4'-Sulfonyldiphenol
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease  
/
HY-P4153 Enlicitide chloride
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.
PCSK9  
Blood or Cardio-cerebrovascular Disease  
/
HY-B1770 Sodium Iodide,99%
Sodium Iodide is a compound composed of sodium ions and iodine ions. Sodium Iodide scavenges hydrogen peroxide. Sodium Iodide maintains the level of thyroid hormone T3 through its iodine component. Sodium Iodide protects tissues from oxidative damage and regulates thyroid homeostasis. Sodium Iodide relieves acute myocardial infarction.
Environmental Pollutants   Biochemical Assay Reagents  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-160623 Rentosertib
Rentosertib (INS018 055) (compound 112) is the orally active TNIK and MAP4K4 inhibitor with IC50 values of 12-120, 12-120 nM, respectively.
MAP4K   TGF-beta/Smad   Cadherin   Interleukin Related  
Colorectal Cancer   Prostate Cancer   Digestive System Inflammation   Obesity   Lung Fibrosis  
/
HY-P71469 Cardiac troponin I/Tnni3 Protein, Mouse (His-SUMO)
Cardiac troponin I, also known as Tnni3, plays a key role as an inhibitory subunit in the troponin complex, a key regulator of calcium sensitivity in actomyosin ATPase activity in striated muscle.Tnni3 interacts with TRIM63, emphasizing its involvement in complex cellular processes.Cardiac troponin I/Tnni3 Protein, Mouse (His-SUMO) is the recombinant mouse-derived Cardiac troponin I/Tnni3 protein, expressed by E.coli , with N-SUMO, N-6*His labeled tag.

Species: Mouse; Source: E. coli

/
HY-P70006 Desmin/DES Protein, Human (His)
Desmin is a muscle-specific type III intermediate filament that is critical for muscle structural integrity. It forms myofibrils, interconnects Z-disks and strengthens muscle fibers. Desmin/DES Protein, Human (His) is the recombinant human-derived Desmin/DES protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P702827 ELAVL1 Protein, Human (Flag)
ELAVL1 Protein, Human (Flag) is the recombinant human-derived ELAVL1, expressed by E. coli , with C-Flag labeled tag.

Species: Human; Source: E. coli

/
HY-P74502 TPM1 Protein, Human (His)
TPM1 encodes tropomyosin, a key actin-binding component in muscle contraction and cytoskeletal structure. It contains α-helical chains that form a coiled-coil structure that stabilizes actin filaments. TPM1 Protein, Human (His) is the recombinant human-derived TPM1 protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

/
HY-P71698 TTN Protein, Human (His)
The TTN protein is critical for vertebrate striated muscle assembly, establishing microfilament connections that are critical for sarcomeric force balance. TTN coordinates cross-link size and extensibility, shaping sarcomere extensibility and muscle function. TTN Protein, Human (His) is the recombinant human-derived TTN protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P703268 QKI Protein, Human (His, Strep)
QKI Protein, Human (His, Strep) is the recombinant human-derived QKI, expressed by E. coli , with Strep, His labeled tag. ,

Species: Human; Source: E. coli

/
HY-P703295 U2AF2 Protein, Human (His, Strep)
U2AF2 Protein, Human (His, Strep) is the recombinant human-derived U2AF2, expressed by E. coli , with Strep, His labeled tag. ,

Species: Human; Source: E. coli

/
HY-P703348 SUGP1 Protein, Human (His, Strep)
SUGP1 Protein, Human (His, Strep) is the recombinant human-derived SUGP1, expressed by E. coli , with Strep, His labeled tag. ,

Species: Human; Source: E. coli

/
HY-P703646 Tnnt2 Protein, Mouse (His, Flag)
Tnnt2 Protein, Mouse (His, Flag) is the recombinant mouse-derived Tnnt2, expressed by E. coli , with C-6*His, C-Flag labeled tag. ,

Species: Mouse; Source: E. coli

/
HY-P82188 HuR Antibody (YA1933)
HuR Antibody (YA1933) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HuR.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82974 Cardiac Troponin T Antibody (YA2719)
Cardiac Troponin T Antibody (YA2719) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cardiac Troponin T.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81144 Cardiac Troponin I Antibody (YA3484)
Cardiac Troponin I Antibody (YA3484) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cardiac Troponin I.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87990 QK1 Antibody (YA7675)
QK1 Antibody (YA7675) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to QK1.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83837 RBFOX2 Antibody (YA3534)
RBFOX2 Antibody (YA3534) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RBFOX2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P810468 MBNL1 Antibody (YA9767)
MBNL1 Antibody (YA9767) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to MBNL1.

Host: Rabbit; Reactivity: Human, mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83837A RBFOX2 Antibody (YA3534)(PBS only)
RBFOX2 Antibody (YA3534) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RBFOX2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P87045 QKI-6 Antibody (YA6738)
QKI-6 Antibody (YA6738) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to QKI-6.

Host: Mouse; Reactivity: Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87046 QKI-7 Antibody (YA6739)
QKI-7 Antibody (YA6739) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to QKI-7.

Host: Mouse; Reactivity: Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P88300 RBFOX1 Antibody (YA7984)
RBFOX1 Antibody (YA7984) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RBFOX1.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P88300A RBFOX1 Antibody (YA7984)(PBS only)
RBFOX1 Antibody (YA7984) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RBFOX1.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P88529 SERPINB13 Antibody (YA8213)
SERPINB13 Antibody (YA8213) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SERPINB13.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P88529A SERPINB13 Antibody (YA8213)(PBS only)
SERPINB13 Antibody (YA8213) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SERPINB13.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82188A HuR Antibody (YA1933)(PBS only)
HuR Antibody (YA1933) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HuR.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/

Keywords

RNA-binding proteins | Cardiovascular health | Post-transcriptional regulation | RNA splicing | Heart failure | Cardiomyopathy | RBM20 | HuR | QKI | RBFOX | Endothelial barrier function | Cardiac remodeling | Atherosclerosis | Myocardial infarction | RNA therapeutics